Taylor H. Schreiber, MD, PhD
Chief Executive Officer and Co-founder
Taylor is a co-founder of Shattuck Labs and currently serves as Chief Executive Officer and a member of the Board of Directors. Before his appointment as CEO in January 2020, Taylor served as the company’s Chief Scientific Officer. Taylor is the lead inventor of Shattuck’s ARC technology platform. Prior to Shattuck, he served as Chief Scientific Officer of Heat Biologics, Inc. where he was a co-inventor of significant elements of Heat’s ImPACT and ComPACT technology platforms. Taylor was also the co-inventor of Pelican Therapeutics ‘s TNFRSF25 agonist technology where he served as Chairman of the Scientific Advisory Board. Taylor has numerous publications in the field of tumor immunology and immunotherapy, spanning the subjects of cancer vaccines, therapeutic proteins and antibodies, adenosinergic and IDO mediated immunosuppression and regulatory T cell biology. In 2008, he received the best overall research award at the National Student Research Forum, and in 2011 he was nominated as a Future Leader in Cancer Research by the American Association for Cancer Research. Taylor received both his M.D. and Ph.D. degrees from the Sheila and David Fuente Program in Cancer Biology at the University of Miami Miller School of Medicine. He received his B.A. in Biology from Bucknell University.
George Golumbeski, PhD
Chairman of the Board and Former Executive Vice President of Business Development for Celgene
George Golumbeski has more than 30 years of experience in the biotechnology industry. He has a long history of forging collaborations with companies engaged in “cutting edge” science. Currently he is dedicated to working to develop young companies. He is a partner at DROIA Ventures. He currently serves on the Board of Directors of Carrick Therapeutics, Sage Therapeutics, and MorphoSys. George was most recently Executive Vice President of Business Development for Celgene, where he was responsible for forging collaborations with biotechnology companies seeking to bring breakthrough medications to people suffering from cancer and chronic inflammation. He holds a PhD in Genetics from the University of Wisconsin-Madison, and conducted his post-doctoral research in molecular biology at the University of Colorado-Boulder. George holds a bachelor’s degree in biology from the University of Virginia
Portfolio Manager, Lennox Capital Partners, LP
Tyler is Managing Director and Portfolio Manager of Lennox Capital Partners, LP, a special situations and value-oriented investment company active in public and private equity. While at Lennox, Tyler spent over a year working at Arog Pharmaceuticals as the acting CFO, leading their capital markets and business development efforts. Prior to joining Lennox, Tyler worked as a senior analyst at YX Funds, a short-only hedge fund in Dallas. In addition, Tyler started his career in the M&A group at Citigroup in New York. Tyler holds a B.S. in Finance and Business Honors from the University of Texas, where he graduated Summa Cum Laude.
Neil Gibson, PhD
Chief Scientific Officer, Biologics, COI Pharma
Neil has over 25 years of drug development experience and currently serves as chief scientific officer, biologics at COI Pharmaceuticals, where he is responsible for the creation of novel drug discovery companies based on innovative and disruptive technologies. Neil has over 25 years of drug development experience and currently serves as chief scientific officer, biologics at COI Pharmaceuticals, where he is responsible for the creation of novel drug discovery companies based on innovative and disruptive technologies. Neil has held various senior positions within the biotechnology and pharmaceutical industry including senior vice president, BioAtla; chief scientific officer, Regulus Therapeutics; chief scientific officer and oncology therapeutic area head, Pfizer Oncology; and chief scientific officer, OSI Pharmaceuticals. While at Pfizer, Neil was also a member of the Pfizer Oncology Business Unit Executive team. Neil has been involved in the successful discovery, development, and commercialization of four approved oncology drugs, including temozolomide, sorafenib, erlotinib, and crizotinib. While at Regulus he was responsible for leading all research and development efforts resulting in three distinct oligonucleotides being advanced into clinical development and the establishment of human proof of concept with the lead molecule RG-101. Neil has held numerous academic appointments, including associate professor, School of Pharmacy and Comprehensive Cancer Center, University of Southern California, and Fogarty Fellow at the National Cancer Institute, National Institutes of Health. During his career, he has served on the Experimental Therapeutics Study Section of the National Cancer Institute and has been actively involved with the American Association of Cancer Research. He is also a past president of the British Pharmaceutical Students Association. Neil earned his Ph.D. in 1982 from the University of Aston in Birmingham, England.
Co-founder, Redmile Group, LLC
Mr. Lee is a co-founder and portfolio manager at Redmile Group, LLC, a health care-focused investment firm based in San Francisco and New York. Prior to Redmile, he worked as a biotechnology investor at Steeple Capital, and before that at Welch Capital Partners and Prudential Equity Group. Mike holds a B.S. in Molecular and Cellular Biology from the University of Arizona.
Helen M. Boudreau
Former COO of the Bill & Melinda Gates Medical Research Institute
Helen has 30 years of experience across the biotech, pharmaceuticals, consulting and banking industries. Helen was most recently COO of the Bill & Melinda Gates Medical Research Institute, a non-profit biotech focused on diseases that cause mortality, poverty and inequality in low- and middle-income countries. Previously, she served as CFO for public and private biotechs, and served in senior finance roles at Novartis and Pfizer, including CFO for Novartis Global Oncology. Helen is currently a member of the board of Premier, Inc. (NASDAQ: PINC), a healthcare improvement company, and is also on the boards of two private biotech companies. Helen earned a BA in Economics, summa cum laude, from the University of Maryland, and an MBA from the Darden Graduate School of Business at the University of Virginia.
Carrie Brownstein, MD
Chief Medical Officer of Cellectis
Carrie is the Chief Medical Officer of Cellectis, where she is responsible for overseeing clinical research and development. Previously she held several senior leadership positions, including Vice President of Global Clinical Research and Development, Therapeutic Area Head for Myeloid Diseases at Celgene, Executive Director of Clinical Sciences Oncology at Regeneron Pharmaceuticals, and Senior Medical Director of Hematology and Oncology at Hoffman-La Roche (Roche Pharmaceuticals). Prior to her industry career, Dr. Brownstein practiced pediatric hematology and oncology at New York Presbyterian Columbia University and Mount Sinai Medical Center and completed her internship and residency at Columbia Presbyterian Medical Center in New York and her subspecialty training at Memorial Sloan-Kettering Cancer Center. Dr. Brownstein received her M.D. from Tufts University School of Medicine and received her A.B. in Psychology from the University of Michigan.